Introducing…Amanda Patanow, Chief Product & Marketing Officer. A problem-solver, plan designer & doer of the impossible, Amanda operates at the intersection of strategy, storytelling & science, a talent she brings to commercializing our TEMT-RF tech | linkedin.com/in/amandapatan…

A new study in American Society for Nutrition Journals found that eating 1 egg a week was associated with a 47% reduction in Alzheimer’s risk and that those who ate eggs had a reduced buildup of toxic proteins associated with the disease, proteins our TEMT-RF targets. sciencedirect.com/science/articl…

Our origin story starts with an unexpected discovery. Researchers expecting to find that prolonged exposure to electromagnetic waves speeds cognitive decline instead found that TEMT-RF exposure prevented and reversed it in mice with Alzheimer’s | neuroem.com/temt-rf-techno…

The FDA has cleared the first blood test to help diagnose Alzheimer’s, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. It detects amyloid plaques in adults 55+. Early studies have shown these plaques are gently broken up by our TEMT-RF. ow.ly/bSTj50WCx40

Introducing … Our CFO, Marilyn Thompson. Her exceptional talents in GAAP, financial accounting, and strategic planning ensure NeuroEM has the solid financial footing we need as we focus on commercializing our TEMT-RF technology. linkedin.com/in/marilyn-t-a…

Emerging non-drug Alzheimer's therapies using novel techniques like electrical stimulation, light therapy & radio waves also promise to safely stop cognitive decline, inc. our TEMT-RF, which early clinical trials suggest can reverse damage. Allysia Finley ow.ly/1Ktk50WHLO5?

Introducing…Sam Alex Mulder, our Chief of Staff & Operations Manager, whose detail-orientation, strategic thinking, and get-it-done energy will help scale our internal infrastructure while ensuring smooth execution across programs, studies & milestones. ow.ly/rf6350WLCvG

Alzheimer's can seem like a fate worse than death, but a wave of innovation is bringing new hope to the 7 million Americans living with the disease. Read more from our CEO on the emerging non-drug therapies like our TEMT-RF in Medical Device News. infomeddnews.com/chuck-papageor…

Welcome Christopher Rumana, MD, and Johana Vega Leonel, PhD, to our Medical & Scientific Advisory Board! Their expertise in neurosurgery, neuroengineering and healthcare innovation will help advance TEMT-RF from research to real-world impact. ow.ly/N0JL50WNPjo

Celebrating the accomplishments of and contributions by our nation's workforce! Happy Labor Day from the NeuroEM team!

Introducing…Edward Goodwin, PhD, Chief Science Officer. An accomplished molecular biologist & entrepreneur, he leads our scientific vision, interprets clinical/preclinical data & guides our mission to develop non-invasive treatments for cognitive decline. ow.ly/nBoj50WT9e6

Big news! 🚀 Our CEO Chuck Papageorgiou will pitch NeuroEM at the #CONNECTpreneur Forum on Sept 11 in DC. We’re bringing our breakthrough TEMT-RF headset for brain health to the world’s largest investor pitch stage. #Neurotech #BrainHealth #InvestorPitch ow.ly/Asaw50WUh8T

Big news📣 We’re presenting at the CONNECTpreneur Forum tomorrow! CEO Chuck Papageorgiou is 🛫 headed to Washington, D.C., where he'll share plans to bring to market our TEMT-RF headset for brain health on the world’s largest investor pitch stage. tinyurl.com/4bc6fx98

CEO Chuck Papageorgiou hit the stage today at the CONNECTpreneur Big Idea Forum — the world’s largest monthly investor pitch — to share how NeuroEM’s TEMT-RF is poised to change the way cognitive decline is treated with top business leaders, angels, and private investors.

Chuck took to the Big Idea CONNECTpreneur Forum stage to discuss how we are advancing our TEMT-RF technology from groundbreaking research to a commercially viable reality.

Chuck also shared with business leaders, angels, and private investors at the Big Idea @CONNECTpreneur Forum how NeuroEM’s breakthrough TEMT-RF headset is redefining brain health & stopping & reversing cognitive decline from Alzheimer’s w/o drugs. 💠More highlights tomorrow!💠

It was an eventful day yesterday at the Big Idea CONNECTpreneur Forum — the world’s largest monthly investor pitch — where we shared how NeuroEM’s TEMT-RF is on the cusp of revolutionizing the treatment of cognitive decline. 👉 Follow for more highlights from the day!👈

At the Big Idea CONNECTpreneur Forum, CEO Chuck Papageorgiou shared with attendees info on our TEMT-RF headset, demonstrating the prototype used in early clinical trials showing its effectiveness at stopping and reversing cognitive decline from Alzheimer’s…without drugs.

As we look ahead to the commercial launch of our next-gen TEMT-RF headset - demo’d here by our CEO - we’re grateful to groups like the Big Idea CONNECTpreneur Forum for giving us a platform that will help us advance from groundbreaking research to a commercially viable reality.

The push for “transformative treatments” echoes U.S. FDA Commissioner Makary’s priority to accelerate innovative therapies to market—aligning with recent comments from Kennedy and others. #HealthcareInnovation #FDA #PatientAccess ow.ly/BKh050WZp7e